Microbot Medical Showcases LIBERTY Robotic System at Oncology Conference to Drive Commercial Adoption
MBOT sits 38% above its 52-week low of $1.25.
Summary
Microbot Medical is attending the Society of Interventional Oncology annual meeting to showcase its LIBERTY Endovascular Robotic System, aiming to accelerate commercial awareness and adoption during its limited market release.
Key Events · Product Development and Regulatory · MBOT
-
Showcasing LIBERTY System at SIO Conference
Microbot Medical is attending the Society of Interventional Oncology (SIO) annual meeting from February 4-8, 2026, to showcase its LIBERTY Endovascular Robotic System.
-
First Commercial Exhibition During Limited Release
This conference marks the first commercial exhibition of the LIBERTY System since its limited market release commenced in late 2025, allowing the company to engage directly with interventional oncologists.
-
Strategy to Accelerate Commercial Adoption
The company aims to share practical insights from current users and offer hands-on demonstrations to accelerate commercial awareness and adoption of the FDA-cleared robotic system, ahead of a full market release planned for April 2026.
Analysis · MBOT · Industrial Applications And Services
Microbot Medical's participation in the Society of Interventional Oncology annual meeting marks a significant step in the commercialization of its LIBERTY Endovascular Robotic System. This event, serving as the first commercial exhibition during the limited market release, is crucial for gathering physician insights and accelerating market awareness and adoption. The company's strategy to engage directly with interventional oncologists and offer hands-on demonstrations is designed to build commercial traction ahead of the planned full market release in April, which is vital for a medical device company with an FDA-cleared product targeting a multi-billion dollar market.
At the time of this filing, MBOT was trading at $1.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $116.9M. The 52-week trading range was $1.25 to $4.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.